3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
3
Hematologic Neoplasms
3
Adenocarcinoma of Lung
3
Cholangiocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Noonan Syndrome 6
1
Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Granuloma, Plasma Cell
1
Glioblastoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
ALK-positive Non-small Cell Lung Cancer
1
Interventions
Temozolomide
73
Bevacizumab
57
Radiotherapy
40
Radiosurgery
28
Carboplatin
23
Nivolumab
17
Etoposide
17
Cisplatin
17
pembrolizumab
16
Irinotecan
16
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Cyclophosphamide
14
Carmustine
14
Pemetrexed
13
Topotecan
10
Surgical Procedures, Operative
10
Capecitabine
10
Lapatinib
9
Filgrastim
9
Trastuzumab
8
Thalidomide
8
Sunitinib
8
Paclitaxel
8
Lomustine
8
Aminolevulinic Acid
8
encorafenib
7
binimetinib
7
Vincristine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Brain Neoplasms
×
ceritinib
×
Clear all
NCT02336451
2020-04-21
Ascend-7
Novartis
Phase 2
Completed
156 enrolled
39 charts